<DOC>
	<DOCNO>NCT01243723</DOCNO>
	<brief_summary>The purpose study assess efficacy Eductyl versus placebo treatment patient dyschesia .</brief_summary>
	<brief_title>Study Assessing Efficacy Eductyl® Treatment Patients With Dyschesia</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<criteria>Male female age 18 75 year old , Writing consent take part study , Patient dyschesia accord Rome III criteria An intensity inconfort use VAS ( 0 ( inconfort ) 100 mm ( maximal supportable inconfort ) ) equal 40 mm Patient suffer neurologic affection , Rectal diseases include : Current anal ou perianal pain , Current organic injury colon rectum , Current anal injury , Current rectal Prolapse , Current haemorrhoid , Colon inflammatory disease ( ulcero haemorrhagic recto colitis , Crohn disease… ) , Current anorectocolon stenosis ( anastomosis , scar ... ) Patient undergone pain killer ( WHO level II ( except dextropropoxyphen ) III ) last 8 day , Patient undergone antidepressant except treatment regular least 15 day wo n't modify study , Patient constipation treatment except treatment regular least 15 day wo n't modify study Intolerance Eductyl® one component ( potassium tartarate acid , sodium bicarbonate , solid hemisynthethic glyceride , soya lecithin , talc ) Use Eductyl® previous 15 day ( 5 day last 15 day ) , Patient already include clinical trial last month , Pregnant breast feed woman , Woman childbearing potential without contraception , Patient unable read write .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Dyschesia treatment</keyword>
	<keyword>Inconfort relate dyschesia</keyword>
	<keyword>Quality life</keyword>
	<keyword>Bowel function index</keyword>
</DOC>